Department of Thoracic Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China AND Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China AND Department of Pulmonary and Critical Care Medicine, The Affiliated Wenling Hospital of Wenzhou Medical University, Taizhou, China.
Iran J Allergy Asthma Immunol. 2023 Jun 16;22(3):290-298. doi: 10.18502/ijaai.v22i3.13057.
Asthma is a common chronic airway inflammation that produces a healthcare burden on the economy. We aim to obtain a better understanding of the clinical status and disease burden of patients with asthma in China. A retrospective study was carried out based on the computerized medical records in the Jinan Health Medical Big Data Platform between 2011 and 2019 (available data from 38 hospitals). The asthma severity of each patient was assessed retrospectively and categorized as mild, moderate, or severe according to Global Initiative for Asthma 2020 (GINA 2020). The results revealed that the majority (75.0%) of patients suffered from mild asthma. Patients treated with inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) at emergency department visits had lower frequencies of exacerbations compared with non-ICS/LABA-treated patients. The incidence rates for 1, 2, 3, and 4 exacerbation of the patients treated with ICS/LABA are lower than those treated without ICS/LABA (14.49 vs. 15.01%, 11.94% vs. 19.12%, 6.51% vs.12.92% and 4.10% vs. 9.35%). The difference got a statistical significance Chronic obstructive pulmonary disease (COPD) and gastroesophageal reflux disease (GERD), two comorbidities related to asthma, were risk factors for asthma exacerbation. Finally, patients who suffered from exacerbations produced a heavier economic burden compared to the patients who never suffered exacerbations (mean costs are ￥3,339.67 vs. ￥968.45 separately). These results provide a reference for clinicians and patients to obtain a better treatment and therapy strategy management for people living with asthma.
哮喘是一种常见的慢性气道炎症，会给经济带来沉重的医疗负担。我们旨在更好地了解中国哮喘患者的临床状况和疾病负担。本研究基于 2011 年至 2019 年济南卫生医疗大数据平台的计算机病历进行回顾性研究（可获取 38 家医院的数据）。回顾性评估每位患者的哮喘严重程度，并根据 2020 年全球哮喘倡议（GINA 2020）标准分为轻度、中度或重度。结果显示，大多数（75.0%）患者患有轻度哮喘。在急诊科就诊时使用吸入皮质激素（ICS）/长效β-激动剂（LABA）治疗的患者与未使用 ICS/LABA 治疗的患者相比，哮喘恶化的频率较低。ICS/LABA 治疗患者的 1、2、3 和 4 次恶化发生率低于未使用 ICS/LABA 治疗的患者（14.49% vs. 15.01%、11.94% vs. 19.12%、6.51% vs.12.92%和 4.10% vs. 9.35%）。差异具有统计学意义。慢性阻塞性肺疾病（COPD）和胃食管反流病（GERD）这两种与哮喘相关的合并症是哮喘恶化的危险因素。最后，与从未恶化的患者相比，恶化的患者产生了更重的经济负担（平均费用分别为 3339.67 元和 968.45 元）。这些结果为临床医生和患者提供了参考，以获得更好的治疗和治疗策略管理，为哮喘患者提供更好的治疗和治疗策略管理。
